Emily Geiser
Family · Scottsdale, AZNPI 1134731144
Payments from drug & device makers
Across 310 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$828
- Novo Nordisk$584
- AstraZeneca$471
- Amgen$465
- Medtronic$389
- Recordati_rare_diseases_inc.$277
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,016100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $828 |
| Novo Nordisk | 56 | $584 |
| AstraZeneca(2 entities) | 20 | $471 |
| Amgen | 20 | $465 |
| Medtronic | 13 | $389 |
| Recordati_rare_diseases_inc. | 14 | $277 |
| Sanofi-aventis U.S. LLC | 11 | $276 |
| Dexcom, Inc. | 13 | $273 |
| Averitas Pharma Inc. | 11 | $246 |
| Radius Health, Inc. | 13 | $245 |
| Corcept Therapeutics | 11 | $213 |
| Tandem Diabetes Care, Inc. | 11 | $201 |
| Sequel Med Tech, LLC | 4 | $177 |
| Mannkind Corporation | 8 | $127 |
| Ascendis Pharma Endocrinology Inc | 5 | $113 |
| Cequr Corporation | 2 | $108 |
| Insulet Corporation | 6 | $106 |
| Amneal Pharmaceuticals LLC | 5 | $98 |
| Boehringer Ingelheim | 5 | $86 |
| Amphastar Pharmaceuticals, Inc. | 5 | $86 |
| AbbVie | 3 | $65 |
| Currax Pharmaceuticals LLC | 4 | $60 |
| Verity Pharmaceuticals Inc. | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Bayer | 3 | $46 |
| Neurocrine Biosciences, Inc. | 1 | $39 |
| Tolmar, Inc. | 2 | $33 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Embecta Corp. | 1 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Chiesi USA, Inc. | 1 | $28 |
| GSK | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Vivus LLC | 1 | $24 |
| Globus Medical | 1 | $19 |
| Alvogen Inc | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$250
- MINIMED 780G$200
- FARXIGA$113
How this compares
$6,016 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 236 | $312,900 |
| JardianceEmpagliflozin | 135 | $188,571 |
| TrulicityDulaglutide | 70 | $103,660 |
| MounjaroTirzepatide | 74 | $99,192 |
| FarxigaDapagliflozin Propanediol | 71 | $84,067 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $26,624 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $22,371 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $21,646 |
| SynjardyEmpagliflozin/Metformin Hcl | 19 | $19,329 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $17,708 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $17,353 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $15,920 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $13,786 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 83 | $11,566 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $11,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $584 | $312,900236 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $86 | $225,607166 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $828 | $202,852144 claims |
| AstraZenecaFarxiga | $471 | $84,06771 claims |
| AbbVieSynthroid | $65 | $5,12548 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $98 | $2,187258 claims |
| Sanofi-aventis U.S. LLCLantus | $276 | $1,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.
Other family in Scottsdale
- Kaitlyn LouchheimScottsdale$208K
- Jennifer PrinceScottsdale$76K
- Camilla BinksScottsdale$62K
- Jessica TapiaScottsdale$36K
- Dawn MougelScottsdale$34K
- Keegan RussellScottsdale$28K
- Jamie HowardScottsdale$14K
- Anna CramerScottsdale$14K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.